Slingshot members are tracking this event:
European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Type II Variation Application Seeking Expanded Approval for the Treatment of Adults With Advanced Renal Cell Carcinoma
Slingshot Insights Explained
Nov 05, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Type Ii Variation Application, Opdivo, Dvanced Renal Cell Carcinoma, Afinitor, Ema